#99841
Re: Farmas USA
Bueno, La Jolla ayer ya se marcó un -5%
Se está hablando de:
#99842
Re: Farmas USA
DVAX
Mugi , tu que eres joven , je,je ,je y tienes mas tiempo para esperar y veo q con esta te embriaga un optimismo pesimista, que veo como pragmatmismo tambien , Como la vez de aqui hasta Agosto ?con esa news de Mr Trump sobre acelerar la aprobaciony la ATM que esta tiene en marcha, por creo que 90 millones,mas la amenazas de demandas que desde Noviembre circulan por la red mas el señor Adam Feuertein que la puede atacar otra vez mas la sopresa que en el ER no pueda dar, Yo pienso que con esa ATM en marcha nos van a empapelar bien pero como quiera le veo recorrido hasta antes de Agosto hasta 16 si miramos los dos gap que debe tapar.
Creo que hoy toca los 6.40 donde tiene el 2do nivel del R.Fibonacci
--
Tuesday. DVAX has a 1-year high of $23.62 and a 1-year low of $3.20. The stock’s 50-day moving average is $4.09 and its 200-day moving average is $8.04.
Cowen analyst Phil Nadeau reiterated a Buy rating on DVAX, with a price target of $45,
--
#99843
Re: Farmas USA
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Due to the enormous demand for pharmaceutical products containing BoNT, it is estimated that in the USA and Europe, annually more than 600,000 mice are sacrificed for these batch tests.
Their assay could serve in minimizing animal experiments as well as provide a physiological relevant platform for drug-screening of neuroactive compounds.
In the study, the researchers demonstrated that neurons differentiated in vitro from mouse embryonic stem cells cultured on multi-electrode arrays (MEAs) can serve as a physiologically relevant cell-based method for detecting BoNT/A holotoxin and complex. The neuronal cultures formed functional networks composed of a heterogeneous mixture of excitatory and inhibitory neurons and upon treatment for 24 hours with ~ 1 pM BoNT/A holotoxin or Botox a complete silencing of synaptic transmission was observed.
Due to the enormous demand for pharmaceutical products containing BoNT, it is estimated that in the USA and Europe, annually more than 600,000 mice are sacrificed for these batch tests. This large amount of animals and suffering causes considerable ethical concerns. Therefore, there is a high demand for the replacement of the MBA.
In response to this high demand, a novel in vitro assay as an alternative to the widely used in vivo MBA has been developed by Stephen Jenkinson
Read more at: https://medicalxpress.com/news/2017-02-stem-cells-derived-neuronal-networks.html#jCp
Due to the enormous demand for pharmaceutical products containing BoNT, it is estimated that in the USA and Europe, annually more than 600,000 mice are sacrificed for these batch tests. This large amount of animals and suffering causes considerable ethical concerns. Therefore, there is a high demand for the replacement of the MBA.
In response to this high demand, a novel in vitro assay as an alternative to the widely used in vivo MBA has been developed by Stephen Jenkinson
Read more at: https://medicalxpress.com/news/2017-02-stem-cells-derived-neuronal-networks.html#jCp
Due to the enormous demand for pharmaceutical products containing BoNT, it is estimated that in the USA and Europe, annually more than 600,000 mice are sacrificed for these batch tests. This large amount of animals and suffering causes considerable ethical concerns. Therefore, there is a high demand for the replacement of the MBA.
In response to this high demand, a novel in vitro assay as an alternative to the widely used in vivo MBA has been developed by Stephen Jenkinson
Read more at: https://medicalxpress.com/news/2017-02-stem-cells-derived-neuronal-networks.html#jCp
Due to the enormous demand for pharmaceutical products containing BoNT, it is estimated that in the USA and Europe, annually more than 600,000 mice are sacrificed for these batch tests. This large amount of animals and suffering causes considerable ethical concerns. Therefore, there is a high demand for the replacement of the MBA.
In response to this high demand, a novel in vitro assay as an alternative to the widely used in vivo MBA has been developed by Stephen Jenkinson
Read more at: https://medicalxpress.com/news/2017-02-stem-cells-derived-neuronal-networks.html#jCp
Due to the enormous demand for pharmaceutical products containing BoNT, it is estimated that in the USA and Europe, annually more than 600,000 mice are sacrificed for these batch tests. This large amount of animals and suffering causes considerable ethical concerns. Therefore, there is a high demand for the replacement of the MBA.
In response to this high demand, a novel in vitro assay as an alternative to the widely used in vivo MBA has been developed by Stephen Jenkinson
Read more at: https://medicalxpress.com/news/2017-02-stem-cells-derived-neuronal-networks.html#jCp
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#99844
Re: Farmas USA
NDRM
Interesante
Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting
PS: El artículo anterior juro que solo lo que pegado una vez. Rankia....
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#99845
Re: Farmas USA
jajaja!!! Muy bueno eso del "optimismo pesimista"!
Yo con cerrar el primer gap y consolidar los 10$ para ese Pdufa me doy con un canto en los dientes, y ya me parece mucho si no hay otras news que respalden a la compañía, sobretodo en el ámbito de su posición financiera, que ahora mismo es débil. Veremos en el ER de Q4 2016 como de mal está la posición de caja. A estas alturas ya no se espera partner, y lo mejor que nos puede pasar es que algún institucional emocionado suscriba un offering antes de tirar de ATM (creo que eran 250M los aprobados en el último S3 via offerings). En cuanto al pdufa en sí, ya se ha comido 2 CRL con el dichoso heplisav, no sé yo si va a generar mucha euforia con el historial tan pobre que lleva a las espaldas. Los estados de ánimo también cotizan, y DVAX está más bien en depresión.
A mi avisadme cuando llegue a 20$! :D
DVAX
#99846
Re: Farmas USA
BMY
Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Blood-Based Cancer Screening
research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. By combining the power of high intensity cancer DNA sequencing, leading edge computer science and large clinical studies into a diagnostic platform, GRAIL aims to develop highly sensitive blood tests that detect cancer in its early stages to enable earlier intervention with targeted therapies.
As an investor, Bristol-Myers Squibb will gain early access to GRAIL’s comprehensive clinical trial databases that may serve as a rich resource for understanding tumor genomics. Additionally, Bristol-Myers Squibb and GRAIL have agreed to principal terms of a research collaboration that would enable Bristol-Myers Squibb to examine its clinical data using GRAIL’s analytic tools to inform research and development decisions, guide strategies to advance point of care companion diagnostics and potentially improve selection, care and management of patients through more targeted treatments.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#99847
Re: Farmas USA
Bastardo, sobre la Megan y la desregulación burocrática de la FDA:
you could also argue Megan Crowley is an example of an FDA system that works well to quickly address the needs of patients suffering from rare diseases.
The FDA has not been as kind to Amicus Therapeutics ( FOLD) , the small orphan drug company run by John Crowley, Megan's father
Last November, the FDA refused Amicus' request to submit an accelerated approval filing for Galafold, a new therapy to treat Fabry disease. The FDA told Amicus that an additional clinical study of Galafold would be required before the drug could be submitted and reviewed. Amicus estimates collecting the new data will take two years.
In contrast, European drug regulators approved Galafold in May 2016 using the same clinical data FDA deemed insufficient. Amicus is selling Galafold to Fabry patients in Europe but can't do the same in the U.S.
If Trump's FDA rhetoric becomes reality, Amicus might benefit. Will the rest of the biotech industry? Lowering approval standards at FDA is not something most biotech and drug industry executives want to see happen.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#99848
Re: Farmas USA
Hoy parece día de escoger cualquiera que no sea un desastre y subirse a la ola. ¿Alguien tiene puntos de entrada de algo?
«Después de nada, o después de todo/ supe que todo no era más que nada.»